Balentine LLC’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Balentine LLC’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30	Closed	-$2.5K	–	603
2023 Q2	$2.5K	Hold	30	–	–	﹤0.01%	556
2023 Q1	$2.29K	Buy	+30	New	+$2.49K	﹤0.01%	594
2015 Q3	–	Sell	-264	Closed	-$22K	–	483
2015 Q2	$22K	Buy	+264	New	+$20.5K	﹤0.01%	255

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Balentine LLC's XBI Position: Q3 2023 in Review

Balentine LLC sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2023, closing a stake of 30 shares — an estimated $2.5K sold.

Balentine LLC first reported a position in XBI in Q2 2015 and held it in 3 quarters. The position peaked at $22K in Q2 2015. 677 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

Balentine LLC reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2023 after selling out during the quarter.
Balentine LLC sold 30 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $2.5K.
Balentine LLC first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and held it in 3 quarters.
Balentine LLC's State Street SPDR S&P Biotech ETF position peaked at $22K in Q2 2015.
677 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on Balentine LLC's 13F filing for Q3 2023, filed 13 Nov 2023.